A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

144

Enrollment

INDUSTRY

Sponsor class

Stopped Management decision

Conditions

Corneal Infiltrates

Interventions

DRUG: Moxifloxacin/dexamethasone phosphate ophthalmic solution
DRUG: Moxifloxacin ophthalmic solution 0.5%
DRUG: Dexamethasone phosphate solution, 0.1%

Sponsor

Alcon Research